Jon P. Stonehouse Sells 184,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) CEO Jon P. Stonehouse sold 184,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Tuesday, January 11th. The shares were sold at an average price of $15.04, for a total value of $2,767,360.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

NASDAQ:BCRX opened at $15.48 on Friday. The firm’s fifty day moving average is $12.87 and its two-hundred day moving average is $14.51. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of -12.19 and a beta of 2.49. BioCryst Pharmaceuticals, Inc. has a one year low of $8.37 and a one year high of $18.48.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Tuesday, November 2nd. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The company had revenue of $40.99 million during the quarter, compared to analysts’ expectations of $37.75 million. During the same quarter last year, the business posted ($0.26) earnings per share. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -1.26 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Edge Wealth Management LLC boosted its holdings in BioCryst Pharmaceuticals by 40.0% during the fourth quarter. Edge Wealth Management LLC now owns 35,000 shares of the biotechnology company’s stock worth $485,000 after buying an additional 10,000 shares in the last quarter. Diversified Trust Co acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $252,000. Bank of New York Mellon Corp raised its holdings in BioCryst Pharmaceuticals by 1.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 747,821 shares of the biotechnology company’s stock worth $10,747,000 after purchasing an additional 9,508 shares during the period. Captrust Financial Advisors raised its stake in shares of BioCryst Pharmaceuticals by 50.5% during the 3rd quarter. Captrust Financial Advisors now owns 7,817 shares of the biotechnology company’s stock worth $112,000 after buying an additional 2,624 shares during the period. Finally, BNP Paribas Arbitrage SA lifted its holdings in BioCryst Pharmaceuticals by 162.1% during the third quarter. BNP Paribas Arbitrage SA now owns 43,904 shares of the biotechnology company’s stock valued at $631,000 after purchasing an additional 27,151 shares in the last quarter. Hedge funds and other institutional investors own 57.20% of the company’s stock.

Several brokerages have issued reports on BCRX. Oppenheimer initiated coverage on shares of BioCryst Pharmaceuticals in a report on Thursday, December 9th. They issued an “outperform” rating and a $16.00 target price for the company. Zacks Investment Research upgraded BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Royal Bank of Canada cut their target price on BioCryst Pharmaceuticals from $16.00 to $14.00 and set a “sector perform” rating for the company in a research report on Thursday, November 4th. Finally, Barclays reduced their price target on shares of BioCryst Pharmaceuticals from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, November 4th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $19.82.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever.

Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.